 HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc NASDAQ: APLS with a Buy rating and a 75 price target. The analyst expects Apelliss C3 inhibitor, pegcetacoplan, to be approved and become a blockbuster in geographic atrophy GA with peak sales of. 